Xenetic Biosciences, Inc. (OTCBB: XBIO) is developing next-generation biologic drugs and novel oncology therapeutics. The company’s proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs, and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic’s lead product candidates include ErepoXen® for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist® for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is also developing a pipeline of clinical candidates for next generation biologics and novel oncology therapeutics for several orphan disease indications. For more information, visit the company’s website at www.xeneticbio.com